| 31 |
Neu5Gc-mediated high affinity interaction is dispensable for CD22 cis-ligands to regulate B cell signaling |
2024 |
| 32 |
New diaryl-1,2,4-triazolo[3,4-a]pyrimidine hybrids as selective COX-2/sEH dual inhibitors with potent analgesic/anti-inflammatory and cardioprotective properties |
2024 |
| 33 |
New pyrazole/pyrimidine-based scaffolds as inhibitors of heat shock protein 90 endowed with apoptotic anti-breast cancer |
2024 |
| 34 |
New series of 4, 6-diaryl pyrimidines: facile synthesis and antiproliferative activity as dual EGFR/VEGFR-2 inhibitors |
2024 |
| 35 |
Synthesis and characterization of new palladium (II) and silver (I) thiosemicarbazone derived by acenaphthenequinone complexes and their antimicrobial activity |
2024 |
| 36 |
Synthesis new series of 4-pyrazolylquinolinones with apoptotic antiproliferative effects as dual EGFR/BRAFV600E inhibitors |
2024 |
| 37 |
Synthesis, enzyme inhibition, and docking studies of new Schiff bases of disalicylic acid methylene-based derivatives as dual-target antibacterial agents |
2024 |
| 38 |
Tetrahydrocarbazoles incorporating 5-arylidene-4-thiazolinones as potential antileukemia and antilymphoma targeting tyrosine kinase and tubulin polymerase enzymes: Design, synthesis, structural, biological and molecular docking studies |
2024 |
| 39 |
Nicotinonitrile as an essential scaffold in medicinal chemistry: an updated review (2015– present) |
2023 |
| 40 |
Design, synthesis and antiproliferative evaluation of lipidated 1, 3-diaryl propenones and their cyclized pyrimidine derivatives as tubulin polymerization inhibitors |
2023 |
